RT Journal Article
SR Electronic
T1 Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.27.20081893
DO 10.1101/2020.04.27.20081893
A1 Gomes, M. Gabriela M.
A1 Aguas, Ricardo
A1 Corder, Rodrigo M.
A1 King, Jessica G.
A1 Langwig, Kate E.
A1 Souto-Maior, Caetano
A1 Carneiro, Jorge
A1 Ferreira, Marcelo U.
A1 Penha-Gonçalves, Carlos
YR 2020
UL http://medrxiv.org/content/early/2020/05/02/2020.04.27.20081893.abstract
AB As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads, the susceptible subpopulation is depleted causing the rate at which new cases occur to decline. Variation in individual susceptibility or exposure to infection exacerbates this effect. Individuals that are frailer, and therefore more susceptible or more exposed, have higher probabilities of being infected, depleting the susceptible subpopulation of those who are at higher risk of infection, and thus intensifying the deceleration in occurrence of new cases. Eventually, susceptible numbers become low enough to prevent epidemic growth or, in other words, herd immunity is attained. Although estimates vary, it is currently believed that herd immunity to SARS-CoV-2 requires 60–70% of the population to be immune. Here we show that variation in susceptibility or exposure to infection can reduce these estimates. Achieving accurate estimates of heterogeneity for SARS-CoV-2 is therefore of paramount importance in controlling the COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are publicly available. https://www.worldometers.info/coronavirus/#countries